On 6 May 2016, parties in the Intercept Pharmaceuticals Inc. securities litigation reached an agreement to settle the case.  Plaintiffs alleged that Intercept made misstatements and omissions in connection with the negative effects of its lead drug, obeticholic acid.  Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports and deposition testimony about market efficiency.

Additional information is available here.